Cargando…
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
BACKGROUND: Neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease with dementia (PDD), and dementia with Lewy bodies (DLB) share clinical and molecular features. Cerebrospinal fluid (CSF) biomarkers may help the characterization of these diseases, improving the differenti...
Autores principales: | Chiasserini, Davide, Biscetti, Leonardo, Eusebi, Paolo, Salvadori, Nicola, Frattini, Giulia, Simoni, Simone, De Roeck, Naomi, Tambasco, Nicola, Stoops, Erik, Vanderstichele, Hugo, Engelborghs, Sebastiaan, Mollenhauer, Brit, Calabresi, Paolo, Parnetti, Lucilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532764/ https://www.ncbi.nlm.nih.gov/pubmed/28750675 http://dx.doi.org/10.1186/s13195-017-0276-4 |
Ejemplares similares
-
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016) -
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014) -
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016) -
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017) -
Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
por: Parnetti, Lucilla, et al.
Publicado: (2019)